KANGYU Pharmaceuticals: Subsidiary Obtains Approval from the US FDA for the relocation of the production site of Acetic Acid Decarboxylation Injection

Jianyou Group announced that its subsidiary Meitheal recently received approval from the US FDA for the transfer of the production site of desmopressin acetate injection, allowing production at the subsidiary Jianjin Pharmaceutical site. The drug is used for central diabetes insipidus, and the company has invested approximately 4.7752 million yuan in research and development expenses. The approval confirms that the company's sterile injection production line and quality system meet standards, which is expected to have a positive impact in the medium to long term. However, product production and sales are easily affected by uncertain factors, posing risks of sales falling short of expectations.